Zimberelimab
drugOn this page
Also known as Ab-122Ab122Gls-010WBP-3055WBP3055
Summary
Zimberelimab (CHEMBL4297856) is a phase-3 clinical-stage antibody targeting PDCD1; indicated across 22 conditions including hodgkins lymphoma and non-small cell lung carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Targets: 1 (PDCD1)
- Indications: 22 conditions
- Clinical trials: 67
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297856 |
| Name | Zimberelimab |
| Type | Antibody |
| Max phase | 3 |
Also known as: Ab-122, AB-122, Ab122, AB122, Gls-010, GLS-010, WBP-3055, WBP3055, Zimberelimab, ZIMBERELIMAB
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| PDCD1 | programmed cell death 1 (CD279) | Binding | 10.76 | 0% | Q15116 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): PDCD1.
Top Reactome pathways
3 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Co-inhibition by PD-1 | 1 | PDCD1 |
| Potential therapeutics for SARS | 1 | PDCD1 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | 1 | PDCD1 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| B cell apoptotic process | 1 |
| adaptive immune response | 1 |
| negative regulation of tolerance induction | 1 |
| negative regulation of T cell mediated immune response to tumor cell | 1 |
| negative regulation of B cell apoptotic process | 1 |
| apoptotic process | 1 |
| humoral immune response | 1 |
| negative regulation of inflammatory response | 1 |
| regulation of immune response | 1 |
| negative regulation of immune response | 1 |
| negative regulation of T cell receptor signaling pathway | 1 |
| negative regulation of T cell activation | 1 |
| positive regulation of T cell apoptotic process | 1 |
| regulatory T cell apoptotic process | 1 |
| immune system process | 1 |
Indications & clinical
Indications
22 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| Hodgkins lymphoma | 3 | MONDO:0004952 | MONDO:0009348 |
| non-small cell lung carcinoma | 3 | MONDO:0005233 | EFO:0003060 |
| adenocarcinoma | 3 | MONDO:0004970 | EFO:0000228 |
| cervical carcinoma | 3 | MONDO:0005131 | EFO:0001061 |
| neoplasm | 2 | MONDO:0005070 | EFO:0000616 |
| prostate adenocarcinoma | 2 | MONDO:0005082 | EFO:0000673 |
| head and neck squamous cell carcinoma | 2 | MONDO:0010150 | EFO:0000181 |
| melanoma | 2 | MONDO:0005105 | EFO:0000756 |
| rectal cancer | 2 | MONDO:0006519 | EFO:1000657 |
| metastatic prostate carcinoma | 2 | MONDO:0004956 | EFO:0000196 |
| malignant pancreatic neoplasm | 2 | MONDO:0009831 | EFO:1000359 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| exocrine pancreatic carcinoma | 2 | MONDO:0005192 | EFO:0002618 |
| cholangiocarcinoma | 2 | MONDO:0019087 | EFO:0005221 |
| pancreatic ductal adenocarcinoma | 2 | MONDO:0005184 | MONDO:0005184 |
| clear cell adenocarcinoma | 1 | MONDO:0005004 | EFO:0000348 |
| glioblastoma | 0 | MONDO:0018177 | EFO:0000519 |
5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 67.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 36 |
| PHASE1 | 17 |
| PHASE1/PHASE2 | 8 |
| PHASE3 | 5 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05502237 | PHASE3 | ACTIVE_NOT_RECRUITING | Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer |
| NCT05568095 | PHASE3 | ACTIVE_NOT_RECRUITING | A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body |
| NCT05798819 | PHASE3 | NOT_YET_RECRUITING | A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer |
| NCT06431633 | PHASE3 | RECRUITING | Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. |
| NCT05518318 | PHASE3 | UNKNOWN | GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin’s Lymphoma (R/R cHL) |
| NCT03547973 | PHASE2 | RECRUITING | Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread |
| NCT04736173 | PHASE2 | ACTIVE_NOT_RECRUITING | Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer |
| NCT04791839 | PHASE2 | ACTIVE_NOT_RECRUITING | Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer |
| NCT05024097 | PHASE2 | RECRUITING | A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer. |
| NCT05130177 | PHASE2 | ACTIVE_NOT_RECRUITING | Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma |
| NCT05329766 | PHASE2 | ACTIVE_NOT_RECRUITING | A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies |
| NCT05335941 | PHASE2 | ACTIVE_NOT_RECRUITING | A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma |
| NCT05633667 | PHASE2 | RECRUITING | Study of Novel Treatment Combinations in Patients With Lung Cancer |
| NCT05676931 | PHASE2 | ACTIVE_NOT_RECRUITING | Study With Various Immunotherapy Treatments in Participants With Lung Cancer |
| NCT05688215 | PHASE1/PHASE2 | RECRUITING | Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma |
| NCT05724563 | PHASE2 | ACTIVE_NOT_RECRUITING | Domvanalimab and Zimberelimab in Advanced Liver Cancers |
| NCT05824468 | PHASE2 | ACTIVE_NOT_RECRUITING | Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer |
| NCT05872724 | PHASE2 | RECRUITING | Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease) |
| NCT05886634 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma |
| NCT05900765 | PHASE2 | RECRUITING | A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin’s Lymphoma |
| NCT05909436 | PHASE1/PHASE2 | RECRUITING | Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors |
| NCT05915442 | PHASE2 | RECRUITING | Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer |
| NCT06009029 | PHASE2 | NOT_YET_RECRUITING | SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study) |
| NCT06048133 | PHASE2 | RECRUITING | Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) |
| NCT06048484 | PHASE2 | RECRUITING | Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma |
| NCT06055738 | PHASE2 | RECRUITING | Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC |
| NCT06128460 | PHASE2 | NOT_YET_RECRUITING | Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer. |
| NCT06133517 | PHASE2 | ACTIVE_NOT_RECRUITING | PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer |
| NCT06155396 | PHASE2 | RECRUITING | A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer |
| NCT06166589 | PHASE2 | NOT_YET_RECRUITING | Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer |
| NCT06238921 | PHASE1/PHASE2 | RECRUITING | Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases |
| NCT06528483 | PHASE2 | NOT_YET_RECRUITING | Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer |
| NCT06727565 | PHASE2 | ACTIVE_NOT_RECRUITING | Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 |
| NCT06790706 | PHASE2 | RECRUITING | IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers |
| NCT07337447 | PHASE2 | NOT_YET_RECRUITING | Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) |
| NCT07397611 | PHASE2 | RECRUITING | Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC |
| NCT03655483 | PHASE2 | UNKNOWN | Study of GLS-010 Injection in the Treatment of Classical Hodgkin’s Lymphoma |
| NCT03972722 | PHASE2 | UNKNOWN | Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer |
| NCT04262856 | PHASE2 | COMPLETED | Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer |
| NCT04381832 | PHASE1/PHASE2 | COMPLETED | Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
4 molecules share ≥1 primary target. Top 4 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| PYRVINIUM | ChEMBL | Phase 4 (approved) | PDCD1 |
| RIFABUTIN | ChEMBL | Phase 4 (approved) | PDCD1 |
| Gefitinib | PubChem | Approved | PDCD1 |
| Pomalidomide | PubChem | Approved | PDCD1 |
Related Atlas pages
- Genes: PDCD1
- Diseases: Hodgkins lymphoma, non-small cell lung carcinoma, adenocarcinoma, cervical carcinoma
- Drugs: Pyrvinium, Rifabutin, Gefitinib, Pomalidomide